Press release
Pruritus Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market and Companies by DelveInsight | Pfizer, Sanofi, Actavis, AbbVie, Astellas Pharma, Cara Therapeutics, EPI Health, Galderma Laboratories, Ocera Therapeutics
Pruritus Clinical Trials
The Pruritus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Pruritus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pruritus Market.
Request for sample report @ https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Pruritus Pipeline Report:
• Pruritus Companies across the globe are diligently working toward developing novel Pruritus treatment therapies with a considerable amount of success over the years.
• Pruritus companies working in the treatment market are Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others, are developing therapies for the Pruritus treatment
• Emerging Pruritus therapies in the different phases of clinical trials are- KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others are expected to have a significant impact on the Pruritus market in the coming years.
• In March 2024, Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC).
• In June 2023, The U.S. Food and Drug Administration (FDA) approved Bylvay (odevixibat) for treating severe pruritus (itching) in patients aged 12 months and older with Alagille syndrome, a condition that impedes bile flow from the liver to the small intestine.
Pruritus Overview
Pruritus, commonly known as itching, is an uncomfortable sensation on the skin that provokes the urge to scratch. It can be a symptom of various conditions, ranging from minor irritations to serious underlying diseases.
Get a Free Sample PDF Report to know more about Pruritus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Pruritus Drugs Under Different Phases of Clinical Development Include:
• KM-001: Kamari Pharma Ltd
• Volixibat: Mirum Pharmaceuticals
• HSK21542: Haisco Pharmaceuticals
• Masitinib: AB Science
• Tradipitant: Vanda Pharmaceuticals
• Dupilumab: Akron Children's Hospital
• HSK21542 tablet: Xizang Haisco Pharmaceutical
• Linerixibat: GlaxoSmithKline
• EP547: Escient Pharmaceuticals
• Difelikefalin Injection: Vifor Fresenius Medical Care
• QLG2198: Qilu Pharmaceutical (Hainan)
• difelikefalin: Cara Therapeutics, Inc.
• CM310: Keymed Biosciences Co.Ltd
• CLE-400: Clexio Biosciences Ltd.
• Volixibat: Mirum Pharmaceuticals, Inc.
• DBI-001 Gel: DermBiont, Inc.
• ruxolitinib cream: Incyte Corporation
Pruritus Route of Administration
Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Pruritus Molecule Type
Pruritus Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Pruritus Pipeline Therapeutics Assessment
• Pruritus Assessment by Product Type
• Pruritus By Stage and Product Type
• Pruritus Assessment by Route of Administration
• Pruritus By Stage and Route of Administration
• Pruritus Assessment by Molecule Type
• Pruritus by Stage and Molecule Type
DelveInsight's Pruritus Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Pruritus product details are provided in the report. Download the Pruritus pipeline report to learn more about the emerging Pruritus therapies
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Pruritus Therapeutics Market include:
Key companies developing therapies for Pruritus are - Actavis, AbbVie Inc., Astellas Pharma Inc., Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP, Ocera Therapeutics Inc., Pfizer Inc., Sanofi, Trevi Therapeutics, and others.
Pruritus Pipeline Analysis:
The Pruritus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pruritus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pruritus Treatment.
• Pruritus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pruritus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pruritus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pruritus drugs and therapies
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Pruritus Pipeline Market Drivers
• Increasing Prevalence of Skin Disorders, Technological Advancements, are some of the important factors that are fueling the Pruritus Market.
Pruritus Pipeline Market Barriers
• However, High Development Costs, Generic Competition, and other factors are creating obstacles in the Pruritus Market growth.
Scope of Pruritus Pipeline Drug Insight
• Coverage: Global
• Key Pruritus Companies: Kamari Pharma Ltd, Mirum Pharmaceuticals, Haisco Pharmaceuticals, AB Science, Vanda Pharmaceuticals, Akron Children's Hospital, Xizang Haisco Pharmaceutical, GlaxoSmithKline, Escient Pharmaceuticals, Vifor Fresenius Medical Care, Qilu Pharmaceutical (Hainan), Cara Therapeutics, Inc., Keymed Biosciences Co.Ltd, Clexio Biosciences Ltd., Mirum Pharmaceuticals, Inc., DermBiont, Inc., Incyte Corporation, and others
• Key Pruritus Therapies: KM-001, Volixibat, HSK21542, Masitinib, Tradipitant, Dupilumab, HSK21542 tablet, Linerixibat, EP547, Difelikefalin Injection, QLG2198, difelikefalin, CM310, CLE-400, Volixibat, DBI-001 Gel, ruxolitinib cream, and others
• Pruritus Therapeutic Assessment: Pruritus current marketed and Pruritus emerging therapies
• Pruritus Market Dynamics: Pruritus market drivers and Pruritus market barriers
Request for Sample PDF Report for Pruritus Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Pruritus Report Introduction
2. Pruritus Executive Summary
3. Pruritus Overview
4. Pruritus- Analytical Perspective In-depth Commercial Assessment
5. Pruritus Pipeline Therapeutics
6. Pruritus Late Stage Products (Phase II/III)
7. Pruritus Mid Stage Products (Phase II)
8. Pruritus Early Stage Products (Phase I)
9. Pruritus Preclinical Stage Products
10. Pruritus Therapeutics Assessment
11. Pruritus Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pruritus Key Companies
14. Pruritus Key Products
15. Pruritus Unmet Needs
16 . Pruritus Market Drivers and Barriers
17. Pruritus Future Perspectives and Conclusion
18. Pruritus Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-bronchitis-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Progressive Multiple Sclerosis Market: https://www.delveinsight.com/report-store/chronic-progressive-multiple-sclerosis-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market
• Encephalitis Market: https://www.delveinsight.com/report-store/encephalitis-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pruritus Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market and Companies by DelveInsight | Pfizer, Sanofi, Actavis, AbbVie, Astellas Pharma, Cara Therapeutics, EPI Health, Galderma Laboratories, Ocera Therapeutics here
News-ID: 3660132 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Pruritus
Pruritus Therapeutics: A Leading Driver Behind Surge In Dermatological Disorders …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Pruritus Therapeutics Industry Market Size Be by 2025?
The market size of pruritus therapeutics has been witnessing a steady surge in the past few years. It is projected to escalate from $11.89 billion in 2024 to $12.38 billion in 2025, exhibiting a compound annual growth rate…
Advancing Pruritus Therapeutics With Targeted Therapies Industry Trends Gaining …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pruritus Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the pruritus therapeutics market has seen robust growth. The market size, which stands at $11.89 billion in 2024, is forecasted to increase to $12.51 billion in 2025, at a compound…
Evolving Market Trends In The Pruritus Therapeutics Industry: Advancing Pruritus …
The Pruritus Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Pruritus Therapeutics Market Size During the Forecast Period?
In recent times, a strong expansion has been witnessed in the pruritus therapeutics market size. The market that valued at $11.89 billion in…
Pruritus Therapeutics Market - Calming the Itch, Restoring Serenity: Pruritus Th …
Newark, New Castle, USA: The "Pruritus Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pruritus Therapeutics Market: https://www.growthplusreports.com/report/pruritus-therapeutics-market/7974
This latest report researches the industry structure, sales, revenue,…
Pruritus Therapeutics Market - Embrace Soothing Solutions: Pruritus Therapeutics …
Newark, New Castle, USA - new report, titled Pruritus Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Pruritus Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Pruritus Therapeutics market. The report offers an overview of the market, which…
Pruritus Drugs Market Future Innovation Strategies 2028
Global Pruritus Drugs Market: Overview
Transdermal drug delivery system is the most preferred way to inject pruritus drugs. Most of the pruritus drugs that are available in the market are in the semi-solid topical dosage state. It includes forms such as creams, gels, and lotions. These products are quite easy to apply, give no or less pain, and are quicker in terms of delivering desired effect as compared to other drug…
